Suven Life Sciences to Present at AAIC 2026 on Alzheimer's Therapies

Suven Life Sciences Limited announced its participation at the Alzheimer's Association International Conference (AAIC) 2026 in London, UK, from July 12-15, 2026. The company will present five scientific posters detailing updates on its global Phase-3 Masupirdine clinical program for agitation associated with Alzheimer's dementia and its Usmarapride Phase-2 clinical development program. Suven will also showcase broader neuroscience pipeline research, engage with experts, and explore potential partnering opportunities for its CNS portfolio. The presentations include updates on Masupirdine, Usmarapride, and other pipeline candidates like SUVN-I6107, SUVN-L1101142, and SUVN-N9503012.